COA: BST-CarGel is an effective adjunct to microfracture for articular cartilage lesions .
An International Randomized Clinical Trial Evaluating Bst-Cargel, A Novel Scaffold For Cartilage Repair, Demonstrates Superiority Of Repair When Compared With Microfracture Alone Treatment
80 patients with an articular cartilage lesion, located on their femoral condyle, were randomized to undergo microfracture surgery with or without receiving BST-CarGel, to assess the efficacy and safety of BST-CarGel. 12 month results demonstrated that there was significantly greater improvement in quality and quantity of cartilage repair tissue in the BST-CarGel group, in comparison to the microfracture alone. In addition, there were no significant differences between the two groups in regard to safety.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
